This web site was copied prior to January 20, 2005. It is now a Federal record managed by the National Archives and Records Administration. External links, forms, and search boxes may not function within this collection.
Merck & Co., Inc. announced a voluntary withdrawal of Vioxx (rofecoxib)
from the U.S. and worldwide market due to safety concerns of an
increased risk of cardiovascular events (including heart attack and
stroke) in patients on Vioxx. Vioxx is a prescription COX-2
selective, non-steroidal anti-inflammatory drug (NSAID) that was
approved by FDA in May 1999 for the relief of the signs and symptoms
of osteoarthritis, for the management of acute pain in adults, and
for the treatment of menstrual symptoms. Vioxx was later approved for
the relief of the signs and symptoms of rheumatoid arthritis in
adults and children.